Petros Pharmaceuticals, Inc. (PTPI)
OTCMKTS · Delayed Price · Currency is USD
0.005624
-0.000476 (-7.80%)
At close: Jun 2, 2026
Petros Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 5.82 | 5.99 | 7.81 | |
Revenue Growth (YoY) | - | - | - | -2.83% | -23.29% | -18.29% |
Cost of Revenue | - | - | - | 1.63 | 2.29 | 1.6 |
Gross Profit | - | - | - | 4.19 | 3.7 | 6.21 |
Selling, General & Admin | 4.21 | 4.64 | 4.63 | 9.26 | 12.21 | 15.59 |
Research & Development | - | - | - | 2.41 | 1.74 | 1.79 |
Operating Expenses | 4.21 | 4.64 | 4.63 | 14.95 | 19.55 | 24.26 |
Operating Income | -4.21 | -4.64 | -4.63 | -10.76 | -15.85 | -18.05 |
Interest Expense | - | - | - | -0.54 | -0.6 | -0.37 |
Interest & Investment Income | 0.25 | 0.26 | 0.37 | 0.52 | 0.01 | - |
Other Non Operating Income (Expenses) | -0.33 | -0.12 | 3.55 | 2.62 | 0.46 | - |
EBT Excluding Unusual Items | -4.29 | -4.5 | -0.71 | -8.16 | -15.97 | -18.42 |
Asset Writedown | - | - | - | - | -7.46 | - |
Other Unusual Items | - | - | - | - | 3.39 | 9.43 |
Pretax Income | -4.29 | -4.5 | -0.71 | -8.16 | -20.04 | -8.99 |
Earnings From Continuing Operations | -4.29 | -4.5 | -0.71 | -8.16 | -20.04 | -8.99 |
Earnings From Discontinued Operations | 7.47 | 6.41 | -13.61 | - | - | - |
Net Income | 3.19 | 1.91 | -14.32 | -8.16 | -20.04 | -8.99 |
Preferred Dividends & Other Adjustments | 37.2 | 45.6 | 12.48 | 5.65 | - | - |
Net Income to Common | -34.02 | -43.69 | -26.8 | -13.81 | -20.04 | -8.99 |
Shares Outstanding (Basic) | 39 | 28 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 39 | 28 | 0 | 0 | 0 | 0 |
Shares Change (YoY) | 6874.49% | 8641.96% | 268.84% | 5.11% | 90.11% | 103.90% |
EPS (Basic) | -0.86 | -1.56 | -83.47 | -158.71 | -241.98 | -206.31 |
EPS (Diluted) | -0.87 | -1.56 | -83.47 | -158.71 | -241.98 | -206.31 |
Free Cash Flow | -5.86 | -6.73 | -2.6 | -7.63 | -12.8 | -11.86 |
Free Cash Flow Per Share | -0.15 | -0.24 | -8.11 | -87.62 | -154.54 | -272.32 |
Gross Margin | - | - | - | 71.98% | 61.79% | 79.52% |
Operating Margin | - | - | - | -184.84% | -264.44% | -231.05% |
Profit Margin | - | - | - | -237.26% | -334.40% | -115.05% |
Free Cash Flow Margin | - | - | - | -130.99% | -213.57% | -151.86% |
EBITDA | - | -1.81 | -1.8 | -7.48 | -10.25 | -11.17 |
EBITDA Margin | - | - | - | -128.46% | -171.01% | -143.00% |
D&A For EBITDA | - | 2.83 | 2.83 | 3.28 | 5.6 | 6.88 |
EBIT | -4.21 | -4.64 | -4.63 | -10.76 | -15.85 | -18.05 |
EBIT Margin | - | - | - | -184.84% | -264.44% | -231.05% |